Gemma Frisius Fund is a seed capital fund established as a joint venture between KU Leuven, KBC Group, and BNP Paribas Fortis Private Equity to stimulate the creation and growth of KU Leuven spin-off companies. It provides seed and start-up capital to spin-offs commercializing knowledge and research developed at KU Leuven.
56% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deal in the last 12 months vs 2 prior).
Portfolio
13
Fund Size
—
Top Stage
Series B
Last 12 Mo
1
Team
PV
Paul Van Dun
Managing Director
RC
Rudi Cuyvers
Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
16 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| RRuneasi | Seed | — | Feb 2026 |
 Aspect Analytics | Series A | — | Sep 2025 |
 Augustine Therapeutics | Series A | — | Mar 2025 |
| Augustine Therapeutics | Series A | — | Jan 2025 |
| Augustine Therapeutics | Series A | — | Jun 2024 |
 Obulytix | Seed | — | Dec 2023 |
 REIN4CED | Series B | — | Apr 2021 |
| REIN4CED | Series B | — | Jan 2021 |
 Protealis | Series A | — | Jan 2021 |
 ViroVet | Series B | — | May 2020 |
 reMYND | Series B | — | Jan 2018 |
 Complix | Series B | — | Jun 2013 |
| AArcarios | Seed | — | Jan 2010 |
| OOkapi Sciences | Unknown | — | Nov 2008 |
 UgenTec | Seed | $9.3M | — |
| DDname-iT | Unknown | — | — |
Top Co-Investors
PMV9 shared
VIB4 shared
AdBio partners3 shared
Asabys Partners3 shared
Novo Holdings A/S3 shared
Eli Lilly and Company3 shared
Capricorn2 shared
Innovation Global Capital2 shared
Finindus2 shared
Jeito Capital2 shared
Novo Capital2 shared
Newton Biocapital2 shared
Korys2 shared
Angel Invest1 shared
ArcTern Ventures1 shared
Andera Partners1 shared
Vesalius Biocapital1 shared
Gimv1 shared
Omnes Capital1 shared
Last updated: 20 October 2026